Getinge completes MDT takeover bid:
This article was originally published in Clinica
Executive Summary
Getinge Industrier, the Swedish medical device manufacturer, has completed the tender offer for US steriliser producer MDT. Around 93% of outstanding MDT shares were tendered for a price of $5.50 each valuing MDT at around $37 million. Last week Getinge had increased its offer by $1 from the $4.50 it had bid in May (see Clinica No 707, p 15).
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.